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Abstract Ample evidence indicates that sphingosine-1-phos-
phate (SPP) can serve as an intracellular second messenger
regulating calcium mobilization, and cell growth and survival.
Moreover, the dynamic balance between levels of the sphingolipid
metabolites, ceramide and SPP, and consequent regulation of
opposing signaling pathways, is an important factor that
determines whether a cell survives or dies. SPP has recently
also been shown to be the ligand for the EDG-1 family of G-
protein-coupled receptors, which now includes EDG-1, -3, -5, -6
and -8. SPP is thus a lipid mediator that has novel dual actions
signaling inside and outside of the cell. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Sphingosine-1-phosphate (SPP) is a bioactive sphingolipid
metabolite whose importance in cell growth regulation was
discovered in our lab in 1991 [1]. Over the ensuing decade,
we have been constantly intrigued by the wide spectrum of
biological processes, including calcium mobilization, cell
growth, di¡erentiation, survival, motility and cytoskeleton
organization, that were found to be regulated by SPP [2].
Part of this puzzle now seems to be resolved as this sphingo-
lipid metabolite is emerging as a member of a novel class of
lipid mediators that can function as second messengers and as
ligands of cell surface receptors. This review is thus focused
on the dual actions of SPP.
2. Intracellular actions
Some confusion in the literature has arisen concerning the
importance of signaling by sphingolipid metabolites because
the net observed e¡ect can be di¡erent dependent upon the
type of cell, the nature of the stimulus being examined, and
most importantly, the intracellular balance between sphingo-
lipids that may mediate opposing pathways. Ceramide (N-
acyl-sphingosine) is produced by stimulation of sphingomye-
linases or of de novo biosynthesis and plays a prominent role
in stress responses and programmed cell death, known as
apoptosis [3]. In contrast, we have implicated SPP, a metab-
olite of ceramide, as a second messenger in cellular prolifer-
ation [4] and survival [5] and showed that SPP protects cells
from ceramide-mediated apoptosis [5]. Sphingosine kinase, the
enzyme that forms SPP from sphingosine, is activated by
many stimuli as well as growth and survival factors, including
platelet-derived growth factor and serum, nerve growth factor
(NGF), muscarinic acetylcholine agonists, TNF-K, and cross-
linking of the immunoglobulin receptors FcOR1 and FcQR1
(reviewed in [2]). While the intracellular targets of SPP have
not yet been unequivocally identi¢ed, intracellular SPP has
been shown to mobilize calcium from internal sources inde-
pendently of inositol trisphosphate, as well as to a¡ect many
signaling pathways leading to proliferation, such as activation
of ERK and inhibition of SAPK/JNK [5,6], and suppression
of apoptosis [5^9]. As further evidence for the importance of
intracellularly generated SPP, inhibitors of sphingosine kinase
not only block formation of SPP in vivo, they selectively in-
hibit calcium mobilization and cellular proliferation and sur-
vival induced by various stimuli (reviewed in [2]). Thus, we
have suggested that the dynamic balance between levels of
ceramide and sphingosine, which mediate cell growth arrest,
and SPP, which promotes proliferation and survival, and their
regulation of opposing signaling cascades may be important in
determining cell fate. For example, stress stimuli increase cer-
amide and sphingosine levels leading to apoptosis of T lym-
phocytes, whereas survival factors stimulate sphingosine ki-
nase, leading to increased SPP levels, which suppress
apoptosis [5]. In agreement, destruction of oocytes as a result
of chemotherapy-induced ceramide elevation can be prevented
by alteration of the apoptosis-associated sphingolipid-medi-
ated signaling pathways [7]. Moreover, this ceramide/SPP
rheostat is an evolutionarily conserved stress regulatory mech-
anism in£uencing growth and survival of yeast.
The sphingosine kinase/SPP signaling pathway is also crit-
ically involved in mediating TNF-K-induced endothelial cell
activation [10]. Furthermore, the ability of high density lipo-
proteins (HDL) to inhibit cytokine-induced adhesion molecule
expression correlates with its ability to reset the sphingolipid
rheostat [10], which has important implications for the pro-
tective e¡ects of HDL in the development of atherosclerosis
and associated coronary heart disease. Recently, the decisive
balance of sphingosine and SPP has also been shown to de-
termine the allergic responsiveness of mast cells [11], where a
high intracellular concentration of sphingosine acts to inhibit
IgE plus antigen-mediated leukotriene synthesis and cytokine
production by preventing activation of the mitogen-activated
protein kinase ERK pathway and AP-1-mediated transcrip-
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tion [11]. In contrast, high intracellular levels of SPP, which is
also secreted by allergically stimulated mast cells, activate
ERK, leading to hexosaminidase and leukotriene release,
and in combination with a calcium ionophore stimulate cyto-
kine production [11]. Treatment of mast cells with SPP coun-
teracted the inhibitory e¡ects of sphingosine and induced AP-
1, a response reminiscent of its e¡ect on Swiss 3T3 ¢broblasts
[12]. Thus, it is likely that activation of sphingosine kinase is a
critical event in the signaling cascades initiated at FcORI.
In sum, these studies provide new insights into the biolog-
ical functions of intracellularly generated SPP and emphasize
the importance of sphingosine kinase, the enzyme that regu-
lates its formation. Recently, we puri¢ed rat kidney sphingo-
sine kinase to apparent homogeneity [13] and on the basis of
peptide sequences derived from the puri¢ed enzyme, subse-
quently cloned and characterized the ¢rst mammalian sphin-
gosine kinase (SPHK1) [14]. SPHK1 is predominantly a cyto-
solic enzyme, and a hydropathy plot of its predicted amino
acid sequence did not reveal any signal peptide or hydropho-
bic transmembrane sequences. However, SPHK1 does contain
several consensus binding sites for both calcium and calmod-
ulin, although it is not yet clear whether they have a physio-
logical regulatory role. Recently, two genes, LCB4 and LCB5,
were shown to encode sphingosine kinases in the yeast Sac-
charomyces cerevisiae [15]. Moreover, by database searches,
we have identi¢ed homologs of SPHK1 in a number of other
species, including worms, plants and mammals, demonstrating
that the enzyme is encoded by a member of a highly conserved
gene family. Comparison of the predicted amino acid sequen-
ces revealed ¢ve highly conserved domains, which might con-
stitute critical portions of catalytic or substrate binding sites.
Although these domains appear to be unique, several motifs
in the C1 and C3 domains have some sequence homology
with diacylglycerol kinase j [14], another lipid kinase that
after phosphorylation translocates to and regulates the
amount of diacylglycerol in the nucleus [16]. If SPHK1 be-
haves in a similar manner, then it might also function in the
nucleus. Interestingly, transfection of HEK293 human embry-
onic kidney cells or NIH 3T3 mouse ¢broblasts with SPHK1
cDNA resulted in a marked increase in sphingosine kinase
activity and cellular SPP with a concomitant decrease of
sphingosine and, to a lesser extent, of ceramide, although in
no case was there detectable secretion of SPP into the medium
[14,17]. Overexpression of sphingosine kinase also induced cell
proliferation, by promoting the G1 to S phase transition of
the cell cycle, as well as inhibiting the apoptotic response to
serum deprivation or ceramide [17]. Furthermore, we have
recently succeeded in cloning a novel lipid phosphohydrolase
that speci¢cally degrades SPP and induces cell death [18].
Enforced expression of this SPP phosphatase in NIH 3T3
¢broblasts not only decreased SPP and enhanced ceramide
levels, it also markedly diminished survival and induced the
characteristic traits of apoptosis [18]. Collectively, our results
suggest that sphingosine kinase and SPP phosphohydrolase
may regulate the dynamic balance between sphingolipid me-
tabolite levels in mammalian cells and consequently in£uence
cell fate.
3. Extracellular actions: SPP is a ligand for the EDG-1 family
of G-protein-coupled receptors (GPCRs)
Interest in SPP has accelerated recently with our discovery
that it is a ligand of the G-protein-coupled cell surface recep-
tor EDG-1 [6,19]. This rapidly led to the identi¢cation of
several other related receptors, named EDG-3, -5, -6 and -8,
demonstrating that EDG-1 belongs to a family of GPCRs
that bind SPP with high a⁄nity and speci¢city (reviewed in
[20]). We also found that sphinganine-1-phosphate, which is
structurally similar to SPP and only lacks the trans double
bond at the 4 position, binds to EDG-3, EDG-5 [21] and
EDG-6 [22]. In contrast, lysophosphatidic acid (LPA) and
sphingosylphosphorylcholine, two other serum borne lyso-
phospholipids, do not bind to this subfamily of receptors
and it is well established that LPA binds to another family
of EDG receptors, which includes EDG-2, -4 and -7 (reviewed
in [23]). The EDG-1 family of receptors are di¡erentially ex-
pressed, mainly in the cardiovascular and nervous systems,
and are coupled to a variety of G-proteins and thus can reg-
ulate diverse signal transduction pathways culminating in plei-
otropic responses depending on the cell type and relative ex-
pression of EDG receptors (reviewed in [20]).
Although the biological functions of the EDG-1 family of
GPCRs are not completely understood, our recent studies
have implicated EDG-1 in the regulation of cell migration
[24]. Cell migration is crucial for embryonic development,
the in£ammatory immune response, wound healing, and tu-
mor formation and metastasis. We found that binding of SPP
to cells overexpressing the serpentine receptor EDG-1 or to
endothelial cells which constitutively express EDG-1 activates
a pertussis toxin-sensitive Gi protein crucial for chemotaxis.
In agreement, it has been demonstrated that activation of
GKS-coupled receptors and the subsequent release of GLQ
dimers is required to initiate signal transduction leading to
directed cell migration [25]. EDG-6 is expressed mainly in
lymphocytes which are normally exposed to high concentra-
tions of SPP in serum. Because the receptors for known leu-
kocyte chemoattractants, including the chemokines, are
GPCRs, it is tempting to speculate that EDG-6 may also
function as a lymphocyte chemokine receptor.
Regulation of cell motility by SPP/EDG-1 signaling may
have important implications for the function of SPP in angio-
genesis. Endothelial cells play a critical role in angiogenesis,
i.e. new vessel formation from pre-existing ones, or neovascu-
larization [26]. They migrate, proliferate and assemble into
tubes with tight cell^cell junctions to form the vessel. Mural
support cells (pericytes and smooth muscle cells (SMC)) are
then required to seal and provide modulatory functions for
the vessel. Recently, we have demonstrated that SPP has ap-
propriate properties to be considered as a bona ¢de angiogen-
ic factor. For example, it stimulates chemokinetic and chemo-
tactic motility of vascular endothelial cells and other cell types
including SMC, and stimulates angiogenesis in vitro, acting
similarly to the known angiogenic factor basic ¢broblast
growth factor (bFGF) [24]. Because bFGF and SPP have an
additive e¡ect on formation of capillary-like tubes by endo-
thelial cells invading collagen gels, SPP may be a speci¢c type
of angiogenic factor. Interestingly, SPP was even more potent
than the known angiogenic factors, bFGF and vascular endo-
thelial growth factor (VEGF) [27]. To determine whether SPP
regulates angiogenesis in vivo, two groups have recently uti-
lized the Matrigel implant model in athymic mice [28,29]. SPP
dramatically enhanced bFGF-induced angiogenesis ; vascular
density and the appearance of mature vascular structures were
greatly increased [29]. In agreement with our in vitro studies
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[24], SPP also potentiated VEGF-induced in vivo angiogenesis
[29]. Collectively, these studies demonstrate that SPP may
play an important role in platelet-induced angiogenesis and
de¢ne SPP as a novel regulator of this process. It is possible
that SPP also plays a role in normal blood vessel formation
and in injury, when local production of SPP could be in-
creased by release from activated platelets, and extravasation
of intravascular £uid could also present SPP into tissues at
concentrations su⁄cient to promote angiogenesis and wound
healing. Elucidation of the molecular mechanisms by which
SPP regulates angiogenesis might provide clues for develop-
ment of a new class of therapeutic agents to either promote or
block mature neovessel formation through e¡ects on SPP/
EDG-1 signaling.
Less is known of the functions of the other members of the
EDG-1 family. EDG-5 is expressed in the cardiovascular sys-
tem [30] and in the brain during embryogenesis, where its
expression is temporally regulated such that high levels of
expression are found in neuronal cell bodies during early
stages of di¡erentiation and in axons during their outgrowth
[31]. This led to the suggestion that EDG-5 may play an
important role in neuronal development and may steer axons
by regulating their growth and inhibiting their extension [31].
In agreement with this hypothesis, we found that enforced
expression of EDG-5 [21] or EDG-8 [32] in PC12 cells caused
a decrease in NGF-induced neurite outgrowth and increased
the fraction of cells with rounded morphology. Because PC12
cells express EDG-5 [31] and EDG-8 [33] constitutively, it is
likely that SPP-induced neurite retraction in PC12 cells is
mediated through these receptors. Moreover, EDG-5 or
EDG-8 may be the unidenti¢ed cell surface receptors respon-
sible for SPP-induced cell morphology alterations and remod-
eling of the actin cytoskeleton, particularly in neurons. Thus,
SPP synthesized by target tissues could help to guide axons by
regulating axon extension or stabilization through binding to
EDG-5 and/or EDG-8. It is also possible that SPP might play
a role during normal brain development or after traumatic
injury by acting through EDG-5 and possibly EDG-8 to a¡ect
neuritogenesis.
In conclusion, as EDG-1, -3, -5, -6 and -8 are widely ex-
pressed in most cells and tissues, important questions that
should be addressed in the future are their roles in mediating
various biological responses to SPP. It is still an enigma why a
simple sphingolipid metabolite such as SPP would have so
many receptors. Gene knockouts might provide clues to sub-
stantiate the importance of their physiological functions.
Moreover, identi¢cation of additional SPP receptors which
mediate di¡erent responses to SPP will be an exciting area
of future research. SPP analogs with di¡erent speci¢cities
for the di¡erent SPP receptors should be useful to determine
which receptors mediate speci¢c biological responses to SPP.
Identi¢cation of SPP agonists and antagonists may provide
the basis for development of novel therapeutics. Finally, a
challenging but important task is the identi¢cation of the
intracellular targets of SPP.
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